SINGAPORE, July 10, 2013 /PRNewswire/ - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical,
industrial and scientific markets, today provided an update regarding
the legal action, filed in the United States District Court of Ohio in
February 2012, against defendants Saint-Gobain Corporation and Philips
for infringement of Zecotek's U.S. Patent Number 7,132,060. On July 1
and 2, 2013, a technical tutorial and a claim construction (Markman)
hearing were completed before the Court. In the hearing, the Court
considered the meaning of certain technical terminology used in the
patent claim. The date of the Court's decision following the Markman
hearing was not specified.
U.S. Patent No. 7,132,060 was granted to Zecotek on November 6, 2006, is
part of Zecotek's portfolio of over 50 patented and patent pending
novel photonic technologies. The patent covers the substances and
chemical formulations used to grow lutetium fine silicate (LFS)
scintillation crystals which are characterized by their combined high
light yield and ultra-fast decay times and are typically used in
medical scanning devices. The lawsuit alleges that Saint-Gobain's LYSO
crystals infringe Zecotek's patent, and that Philips infringes by using
those crystals in the PET scanners it sells.
Zecotek is joined by its exclusive licensee for certain LFS crystals,
Beijing Opto-Electronics Technology Co. Ltd., as co-plaintiff. Zecotek
is represented by Thomas Loop of Loop Intellectual Property Law and
Justin Nelson of Susman Godfrey LLP. Both firms are recognized leaders
in patent law and intellectual property litigation matters.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics
technology company developing high-performance scintillation crystals,
photo detectors, positron emission tomography scanning technologies, 3D
auto-stereoscopic displays, and lasers for applications in medical,
high-tech and industrial sectors. Founded in 2004, Zecotek operates
three divisions: Imaging Systems, Laser Systems and 3D Display Systems
with labs located in Canada, Korea, Russia, Singapore and U.S.A. The
management team is focused on building shareholder value by
commercializing over 50 patented and patent pending novel photonic
technologies directly and through strategic alliances and joint
ventures with leading industry partners such as the European
Organization for Nuclear Research (Switzerland), Beijing
Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems
(South Korea), and National NanoFab Center (South Korea). For more
information visit www.zecotek.com, follow @zecotek on Twitter and "like" us in Facebook at www.facebook.com/zecotek.
This press release may contain forward-looking statements that are based
on management's expectations, estimates, projections and assumptions.
These statements are not guarantees of future performance and involve
certain risks and uncertainties, which are difficult to predict.
Therefore, actual future results and trends may differ materially from
what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of the content of
this news release. If you would like to receive news from Zecotek in
the future please visit the corporate website at www.zecotek.com.
SOURCE Zecotek Photonics Inc.